International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1297-1304 , April 2010

Stereotactic Body Radiotherapy for Primary Management of Early-Stage, Low- to Intermediate-Risk Prostate Cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee

  • Mark K. Buyyounouski, M.D., M.S.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA
    • Corresponding Author InformationReprint requests to: Mark K. Buyyounouski, M.D., M.S., Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111. Tel: (215) 214-3707; Fax: (215) 214-1629
    • ,
  • Robert A. Price Jr., Ph.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Eleanor E.R. Harris, M.D.

      Affiliations

    • H. Lee Moffitt Cancer Center, Tampa, FL
    • ,
  • Robert Miller, M.D.

      Affiliations

    • Mayo Clinic and Mayo Foundation, Rochester, MN
    • ,
  • Wolfgang Tomé, Ph.D.

      Affiliations

    • University of Wisconsin, Madison, WI
    • ,
  • Tracey Schefter, M.D.

      Affiliations

    • University of Colorado Health Services, Denver, CO
    • ,
  • E. Ishmael Parsai, Ph.D.

      Affiliations

    • University of Toledo Health Science Campus, Toledo, OH
    • ,
  • Andre A. Konski, M.D., M.B.A.

      Affiliations

    • Wayne State University School of Medicine, Detroit, MI
    • ,
  • Paul E. Wallner, D.O.

      Affiliations

    • 21st Century Oncology, Inc., Moorestown, NJ

Received 4 September 2009 ,Accepted 8 September 2009.

References 

  1. Kavanagh BD, Timmerman RD, Benedict SH, et al. How should we describe the radioblologic effect of extracranial stereotactic radlosurgery: Equivalent uniform dose or tumor control probability?. Med Phys. 2003;30:321–324
  2. Chang BK, Timmerman RD. Stereotactic body radiation therapy: A comprehensive review. Am J Clin Oncol. 2007;30:637–644
  3. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  4. Haustermans K, Hofland I, Poppel H, et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:1067–1070
  5. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  6. Hanks GE, Schultheiss TE, Hanlon AL, et al. Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study. Int J Radiat Oncol Biol Phys. 1997;37:543–550
  7. Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:747–748
  8. King CR, Mayo CS. Is the prostrate alpha/beta ratio of 1.5 from Brenner & Hall a modeling artifact. Int J Radiat Oncol Biol Phys. 2000;47:536–539
  9. Brenner DJ. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:315–316
  10. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  11. Logue JP, Cowan RA, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:1522–1523
  12. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys. 2001;51:213–214
  13. D'Souza WD, Thames HD. Is the alpha/beta ratio for prostate cancer low?. Int J Radiat Oncol Biol Phys. 2001;51:1–3
  14. King CR, Fowler JF. Yes, the alpha/beta ratio for prostate cancer is low or “methinks the lady doth protest too much…about a low alpha/beta that is”. Int J Radiat Oncol Biol Phys. 2002;54:626–627author reply 627–628
  15. Dale RG, Jones B. Is the alpha/beta for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021–1031. Int J Radiat Oncol Biol Phys. 2002;52:1427–1428author reply 1428
  16. Lee WR. In regard to Brenner et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio) similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;53:1392;author reply 1393
  17. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;55:194–203
  18. Amer AM, Mott J, Mackay RI, et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:199–207
  19. Lindsay PE, Moiseenko VV, Van Dyk J, et al. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer. Phys Med Biol. 2003;48:507–522
  20. Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57:391–401
  21. Kal HB, Van Gellekom MP. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;57:1116–1121
  22. Brenner DJ. Hypofractionation for prostate cancer radiotherapy—what are the issues?. Int J Radiat Oncol Biol Phys. 2003;57:912–914
  23. Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1013–1015
  24. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol). 2007;19:289–301
  25. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  26. Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;56:1093–1104
  27. Brenner D, Armour E, Corry P, et al. Sublethal damage repair times for a late-responding tissue relevant to brachytherapy (and external-beam radiotherapy): Implications for new brachytherapy protocols. Int J Radiat Oncol Biol Phys. 1998;41:135–138
  28. van der Kogel AJ, Jarrett KA, Paciotti MA, et al. Radiation tolerance of the rat rectum to fractionated X-rays and pi-mesons. Radiother Oncol. 1988;12:225–232
  29. Dewit L, Oussoren Y, Bartelink H, et al. The effect of cis-diamminedichloroplatinum(II) on radiation damage in mouse rectum after fractionated irradiation. Radiother Oncol. 1989;16:121–128
  30. Terry NH, Denekamp J. RBE values and repair characteristics for colo-rectal injury after caesium 137 gamma-ray and neutron irradiation. II. Fractionation up to ten doses. Br J Radiol. 1984;57:617–629
  31. Dubray BM, Thames HD. Chronic radiation damage in the rat rectum: An analysis of the influences of fractionation, time and volume. Radiother Oncol. 1994;33:41–47
  32. Gasinska A, Dubray B, Hill SA, et al. Early and late injuries in mouse rectum after fractionated X-ray and neutron irradiation. Radiother Oncol. 1993;26:244–253
  33. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47:103–113
  34. Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003;56:192–198
  35. Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:1260–1268
  36. Akimoto T, Muramatsu H, Takahashi M, et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2004;60:1033–1039
  37. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–6138
  38. Yeoh EE, Fraser RJ, McGowan RE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys. 2003;55:943–955
  39. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64:518–526
  40. Pollack A, Li T, Buyyounouski M, et al. Defining the α/β ratio for prostate cancer: Results of a randomized radiotherapy hypofractionation trial. Paper presented at the Genitourinary Cancers Symposium; February 26–28, 2009; Orlando, Florida.
  41. Kupelian PA, Reddy CA, Carlson TP, et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:904–912
  42. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic Experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  43. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63:1463–1468
  44. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57:1254–1259
  45. Ritter MA, Forman JD, Kupelian PA, et al. A Phase I/II trial of dose-per-fraction escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69:S174
  46. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105
  47. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043–1048
  48. Pawlicki T, Cotrutz C, King C. Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol. 2007;40:395–406
  49. Choi C, Cho C, Kim G, et al. Stereotactic radiation therapy of localized prostate cancer using Cyberknife (Abstr.). Int J Radiat Oncol Biol Phys. 2007;69:S375
  50. Park K, Kim KH, Jo MK, et al. Feasibility of Cyberknife for the treatment of localized prostate cancer: Preliminary results (Abstr.). Eur Urol Suppl. 2006;5:132
  51. Fuller DB, Lee C, Hardy S, et al. Virtual HDR Cyberknife prostate treatment: Toward the development of non-invasive HDR dosimetry delivery and early clinical observations (Abstr.). Int J Radiat Oncol Biol Phys. 2007;69:S358
  52. Mantz CA, Fernandez E, Harrison S, et al. A phase II trial of Trilogy-based prostate SBRT: Initial report of favorable acute toxicity outcomes (Abstr.). Int J Radiat Oncol Biol Phys. 2007;69:S334

 Emerging Technology Committee Note: Assignment of this project to the Task Group was made on November 19, 2007, and data collection for preparation of the full report available on the American Society for Therapeutic Radiology and Oncology (ASTRO) website and this condensed version was closed on March 26, 2008. Clinical, physics, or biology data and regulatory revisions available after that date are not included in this review.

 Disclaimers and Notifications: This document was prepared by the ASTRO Emerging Technology Committee (ETC).

 Before initiation of this evaluation project, all members of the ETC and of the task group performing the evaluation were required to complete conflict of interest statements specifically related to the devices or procedures involved. These statements are maintained in the file at ASTRO headquarters in Fairfax, VA, and pertinent conflict information will be published with the report. Individuals with disqualifying conflicts are recused from participation in ASTRO emerging technology assessments.

 The primary role of the ETC is to provide technology assessments regarding emerging technologies to various stakeholders within and outside the Society. It is not the role of the Committee to develop or defend code definitions, valuation recommendations, or other payment policy development functions.

 ASTRO Emerging Technology Reports present scientific, health, and safety information and may to some extent reflect scientific or medical opinion. They are made available to ASTRO members and to the public for educational and informational purposes only. Any commercial use of any content in this report without the prior written consent of ASTRO is strictly prohibited.

 ASTRO does not make or imply any warranties concerning the safety or clinical efficacy of the devices reviewed in this report. ASTRO assumes no liability for the information, conclusions, and findings contained in its Emerging Technology Reports.

 This report is subject to the ASTRO copyright restrictions.

 ASTRO considers any consideration of its technology assessment reports to be voluntary, with the ultimate determination regarding any technology's application to be made by the practitioner, in consultation with the patient, in light of each patient's individual circumstances in accordance with applicable law. Decisions regarding coverage of a technology, device, or procedure are made by payors and government agencies in accordance with applicable legal standards and their decision-making processes. In addition, this technology assessment describes the use of devices or procedures; it cannot be assumed to apply to the use of these interventions performed in the context of clinical trials, given that clinical studies are designed to evaluate or validate innovative approaches in a disease for which improved staging and treatment are needed or are being explored. In that assessment development involves a review and synthesis of the latest literature, a technology assessment also serves to identify important questions and settings for further research.

 Conflict of interest: none.

PII: S0360-3016(09)03543-3

doi: 10.1016/j.ijrobp.2009.09.078

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1297-1304 , April 2010

Article Tools